Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jenny Jing Li is originally from China. She earned her undergraduate degree from Duke University where she majored in neuroscience and biology. She received her M.D. degree from Duke University School of Medicine and completed her Internal Medicine residency at University of Texas Southwestern Medical Center. She is currently undergoing her hematology/oncology fellowship training at Mayo Clinic in Rochester, MN

Lung Cancer Video Library Mandarin - Does Immunotherapy Work with Driver Mutations like EGFR, ALK
Lung Cancer Video Library - Mandarin
Author
Jenny J. Li, MD, GRACE Guest Faculty
Image

For our Mandarin speaking community, Jenny J. Li, MD, Hematology/Oncology Fellow at the Mayo Clinic in Rochester MN, offers translated updates to our Lung Cancer Video Library. 

In this video translation, Dr. Li discusses whether immunotherapy works in patients with driver mutations like EGFR and ALK.


We would like to thank the following sponsors:
Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.
Image
Videoteca de Cáncer de Pulmon - 2025
Video
Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.
Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.